↓ Skip to main content

EVI1 promotes tumor growth via transcriptional repression of MS4A3

Overview of attention for article published in Journal of Hematology & Oncology, March 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EVI1 promotes tumor growth via transcriptional repression of MS4A3
Published in
Journal of Hematology & Oncology, March 2015
DOI 10.1186/s13045-015-0124-6
Pubmed ID
Authors

Gerwin Heller, Anna Rommer, Katarina Steinleitner, Julia Etzler, Hubert Hackl, Petra Heffeter, Erwin Tomasich, Martin Filipits, Birgit Steinmetz, Thais Topakian, Simone Klingenbrunner, Barbara Ziegler, Andreas Spittler, Sabine Zöchbauer-Müller, Walter Berger, Rotraud Wieser

Abstract

The transcription factor Ecotropic Virus Integration site 1 (EVI1) regulates cellular proliferation, differentiation, and apoptosis, and its overexpression contributes to an aggressive course of disease in myeloid leukemias and other malignancies. Notwithstanding, knowledge about the target genes mediating its biological and pathological functions remains limited. We therefore aimed to identify and characterize novel EVI1 target genes in human myeloid cells. U937T_EVI1, a human myeloid cell line expressing EVI1 in a tetracycline regulable manner, was subjected to gene expression profiling. qRT-PCR was used to confirm the regulation of membrane-spanning-4-domains subfamily-A member-3 (MS4A3) by EVI1. Reporter constructs containing various parts of the MS4A3 upstream region were employed in luciferase assays, and binding of EVI1 to the MS4A3 promoter was investigated by chromatin immunoprecipitation. U937 derivative cell lines experimentally expressing EVI1 and/or MS4A3 were generated by retroviral transduction, and tested for their tumorigenicity by subcutaneous injection into severe combined immunodeficient mice. Gene expression microarray analysis identified 27 unique genes that were up-regulated, and 29 unique genes that were down-regulated, in response to EVI1 induction in the human myeloid cell line U937T. The most strongly repressed gene was MS4A3, and its down-regulation by EVI1 was confirmed by qRT-PCR in additional, independent experimental model systems. MS4A3 mRNA levels were also negatively correlated with those of EVI1 in several published AML data sets. Reporter gene assays and chromatin immunoprecipitation showed that EVI1 regulated MS4A3 via direct binding to a promoter proximal region. Experimental re-expression of MS4A3 in an EVI1 overexpressing cell line counteracted the tumor promoting effect of EVI1 in a murine xenograft model by increasing the rate of apoptosis. Our data reveal MS4A3 as a novel direct target of EVI1 in human myeloid cells, and show that its repression plays a role in EVI1 mediated tumor aggressiveness.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 19%
Researcher 5 16%
Student > Ph. D. Student 5 16%
Student > Bachelor 4 13%
Student > Doctoral Student 1 3%
Other 3 10%
Unknown 7 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 12 39%
Medicine and Dentistry 4 13%
Computer Science 2 6%
Immunology and Microbiology 2 6%
Psychology 1 3%
Other 1 3%
Unknown 9 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2018.
All research outputs
#7,215,016
of 22,805,349 outputs
Outputs from Journal of Hematology & Oncology
#482
of 1,191 outputs
Outputs of similar age
#85,726
of 262,802 outputs
Outputs of similar age from Journal of Hematology & Oncology
#4
of 25 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,191 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,802 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.